Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7447421 | 0.84 | DGAT1 (0.40) | DGAT1KLKB1PDE10AP2RX7 | |
| SCHEMBL616813 | 0.81 | DGAT1 (0.48) | DGAT1KLKB1PDE10A | |
| SCHEMBL21265981 | 0.81 | — | — | |
| SCHEMBL19404674 | 0.80 | DGAT1 (0.47) | DGAT1KLKB1PDE10A | |
| SCHEMBL14150942 | 0.79 | KLKB1 (0.36) | DGAT1KLKB1PDE10A | |
| SCHEMBL21049984 | 0.79 | DGAT1 (0.43) | DGAT1KLKB1PDE10A | |
| SCHEMBL13734146 | 0.77 | DGAT1 (0.40) | DGAT1KLKB1 | |
| SCHEMBL15701589 | 0.77 | DGAT1 (0.40) | DGAT1KLKB1 | |
| SCHEMBL23124128 | 0.77 | DGAT1 (0.50) | DGAT1PDE10A | |
| SCHEMBL14901223 | 0.77 | DGAT1 (0.47) | DGAT1KLKB1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | disclosed |
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3535258-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018093569-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-2552208-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| WO-2011123609-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | KCNB1, CACNA1E, GRK1 | DGAT1 1958/4885KLKB1 2590/4885PDE10A 1501/4885 |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | KCNB1, CACNA1E, GRK1 | DGAT1 1958/4885KLKB1 2590/4885PDE10A 1501/4885 |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | DGAT1 4593/4885KLKB1 1175/4885PDE10A 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.